MedTrace Logo

Ibudilast in the Treatment of Medication Overuse Headache

NCT01317992 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-02-06

No results posted yet for this study

Summary

The purpose of this study is to determine if ibudilast is effective in reverting patients with medication overuse headache suffering chronic daily headache back to their original episodic headache pattern.

Conditions

  • Medication Overuse Headache

Interventions

DRUG

Ibudilast

Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.

DRUG

Placebo

Placebo 4 capsules, orally, twice daily for 8 weeks.

Sponsors & Collaborators

  • University of South Australia

    collaborator OTHER

  • University of Adelaide

    lead OTHER

Principal Investigators

  • Paul Rolan, MD FRACP · The University of Adelaide

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-06-30
Completion
2013-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317992 on ClinicalTrials.gov